Lilly Withdraws Application For Additional U.S. Indication For Cymbalta(R) For Chronic Pain Eli Lilly and Company (NYSE: LLY) has withdrawn its supplemental New Drug Application (sNDA) from the U.S. Food and Drug Administration (FDA) for Cymbalta(R) (duloxetine HCl) for the management of chronic pain. Lilly plans to resubmit the application in the first half of 2009, adding data from a recently completed positive study in chronic osteoarthritis pain of the knee.
Source: www.medicalnewstoday.comElectric Fields Clean Up Bioreactors Researchers from EKB Technology - a spinout joint venture between the University of Oxford and C-Tech Innovation - have announced positive results from an elegant method of improving mammalian cell bioreactors. Bioreactors are used to manufacture proteins for
medicines, and the researchers have show that a mild electric field can successfully extract unwanted by-product chemicals from the bioreactor.
Source: www.medicalnewstoday.com
# posted by Network @ 9:00 AM
